Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Risk of preterm and early term birth by maternal drug use

Abstract

Objective

Examine the risk of preterm birth (PTB, < 37 weeks) and early term birth (37–38 weeks) for women with reported drug abuse/dependence.

Study Design

The population was drawn from singleton livebirths in California from 2007 to 2012. Drug abuse/dependence was determined from maternal diagnostic codes (opioid, cocaine, cannabis, amphetamine, other, or polysubstance). Relative risks, adjusted for maternal factors were calculated for PTB and early term birth.

Result

Of the 2,890,555 women in the sample, 1.7% (n = 48,133) had a diagnostic code for drug abuse/dependence. The percentage of PTBs varied from 11.6% (cannabis) to 24.3% (cocaine), compared with 6.7% of women without reported drug abuse/dependence.

Conclusion

Women with reported drug abuse/dependence during pregnancy were at increased risk of having a PTB and all but those using cannabis were at risk of having an early term birth. Women using cocaine and polysubstance were at the highest risk of birth < 32 weeks.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014;345:760–5.

    CAS  Article  Google Scholar 

  2. 2.

    Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84.

    Article  Google Scholar 

  3. 3.

    Machado LC Jr., Passini R Jr., Rosa IR, Carvalho HB. Neonatal outcomes of late preterm and early term birth. Eur J Obstet Gynecol Reprod Biol. 2014;179:204–8.

    Article  Google Scholar 

  4. 4.

    Reddy UM, Bettegowda VR, Dias T, Yamada-Kushnir T, Ko CW, Willinger M. Term pregnancy: a period of heterogeneous risk for infant mortality. Obstet Gynecol. 2011;117:1279–87.

    Article  Google Scholar 

  5. 5.

    Bonello MR, Xu F, Li Z, Burns L, Austin MP, Sullivan EA. Mental and behavioral disorders due to substance abuse and perinatal outcomes: a study based on linked population data in New South Wales, Australia. Int J Environ Res Public Health. 2014;11:4991–5005.

    Article  Google Scholar 

  6. 6.

    Burns L, Mattick RP, Cooke M. The use of record linkage to examine illicit drug use in pregnancy. Addiction. 2006;101:873–82.

    Article  Google Scholar 

  7. 7.

    Feldman JG, Minkoff HL, McCalla S, Salwen M. A cohort study of the impact of perinatal drug use on prematurity in an inner-city population. Am J Public Health. 1992;82:726–8.

    CAS  Article  Google Scholar 

  8. 8.

    Gorman MC, Orme KS, Nguyen NT, Kent EJ 3rd, Caughey AB. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014;211:429.e421–27.

    Article  Google Scholar 

  9. 9.

    Hayatbakhsh MR, Flenady VJ, Gibbons KS, Kingsbury AM, Hurrion E, Mamun AA, et al. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res. 2012;71:215–9.

    Article  Google Scholar 

  10. 10.

    Ladhani NN, Shah PS, Murphy KE. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011;205:219.e211–7.

    Article  Google Scholar 

  11. 11.

    Brown HL, Graves CR. Smoking and marijuana use in pregnancy. Clin Obstet Gynecol. 2013;56:107–13.

    Article  Google Scholar 

  12. 12.

    Ganapathy V. Drugs of abuse and human placenta. Life Sci. 2011;88:926–30.

    CAS  Article  Google Scholar 

  13. 13.

    Ganapathy VV, Prasad PD, Ganapathy ME, Leibach FH. Drugs of abuse and placental transport. Adv Drug Deliv Rev. 1999;38:99–110.

    CAS  Article  Google Scholar 

  14. 14.

    Huizink AC. Prenatal cannabis exposure and infant outcomes: overview of studies. Prog Neuropsychopharmacol Biol Psychiatry. 2014;52:45–52.

    CAS  Article  Google Scholar 

  15. 15.

    Kuczkowski KM. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol. 2007;19:578–85.

    Article  Google Scholar 

  16. 16.

    Woods JR Jr, Plessinger MA, Clark KE. Effect of cocaine on uterine blood flow and fetal oxygenation. JAMA. 1987;25:957–61.

    Article  Google Scholar 

  17. 17.

    Morgan MA, Silavin SL, Randolph M, Payne GG Jr, Sheldon RE, Fishburne JI Jr, et al. Effect of intravenous cocaine on uterine blood flow in the gravid baboon. Am J Obstet Gynecol. 1991;16:1021–7. ; discussion1027-30

    Article  Google Scholar 

  18. 18.

    Gillogley KM, Evans AT, Hansen RL, Samuels SJ, Batra KK. The perinatal impact of cocaine, amphetamine, and opiate use detected by universal intrapartum screening. Am J Obstet Gynecol. 1990;163(5 Pt 1):1535–42.

    CAS  Article  Google Scholar 

  19. 19.

    Cherukuri R, Minkoff H, Feldman J, Parekh A, Glass L. A cohort study of alkaloidal cocaine (“crack”) in pregnancy. Obstet Gynecol. 1988;72:147–51.

    CAS  PubMed  Google Scholar 

  20. 20.

    Dekker GA, Lee SY, North RA, McCowan LM, Simpson NA, Roberts CT. Risk factors for preterm birth in an international prospective cohort of nulliparous women. PLoS ONE. 2012;7:e39154.

    CAS  Article  Google Scholar 

  21. 21.

    Saurel-Cubizolles MJ, Prunet C, Blondel B. Cannabis use during pregnancy in France in 2010. BJOG. 2014;121:971–7.

    Article  Google Scholar 

  22. 22.

    Chouteau M, Namerow PB, Leppert P. The effect of cocaine abuse on birth weight and gestational age. Obstet Gynecol. 1988;72(3 Pt 1):351–4.

    CAS  PubMed  Google Scholar 

  23. 23.

    American Medical Association. International classification of diseases: ICD-9-CM 2008. Vol. 1, 2. Chicago, IL: American Medical Association; 2007.

  24. 24.

    Baer RJ, Norton ME, Shaw GM, Flessel MC, Goldman S, Currier RJ, et al. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. Am J Obstet Gynecol. 2014;211:675 e671–19.

    Article  Google Scholar 

  25. 25.

    Jelliffe-Pawlowski LL, Baer RJ, Blumenfeld YJ, Ryckman KK, O’Brodovich HM, Gould JB, et al. Maternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth. BJOG. 2015;122:1484–93.

  26. 26.

    Administration SAaMHS. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.

  27. 27.

    McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol. 2005;193(3 Pt 1):606–10.

    CAS  Article  Google Scholar 

  28. 28.

    Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2010;32:406–13.

    CAS  Article  Google Scholar 

  29. 29.

    Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009;201:326.e321–6.

    Article  Google Scholar 

  30. 30.

    Kotelchuck M. An evaluation of the Kessner adequacy of prenatal care index and a proposed adequacy of prenatal care utilization index. Am J Public Health. 1994;84:1414–20.

    CAS  Article  Google Scholar 

  31. 31.

    El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylack L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol. 2003;23:354–60.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the California Preterm Birth Initiative within the University of California, San Francisco.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Rebecca J. Baer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baer, R.J., Chambers, C.D., Ryckman, K.K. et al. Risk of preterm and early term birth by maternal drug use. J Perinatol 39, 286–294 (2019). https://doi.org/10.1038/s41372-018-0299-0

Download citation

Further reading

Search

Quick links